Showing results (1-10 of 180) with videos related to

Sort By:
Pageof 18
Lancet Regional Health. Americas|February 13, 2023
Scaling up investigation and treatment of household contacts of tuberculosis patients in Brazil: a cost-effectiveness and budget impact analysisMayara Lisboa Bastos, Olivia Oxlade, Jonathon R Campbell, et al.
Lancet (London, England)|March 8, 2025
TuberculosisAnete Trajman, Jonathon R Campbell, Tenzin Kunor, et al.
Current Opinion in Pulmonary Medicine|April 9, 2010
Occupational respiratory infectionsAnete Trajman, Dick Menzies
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 14, 2020
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized TrialsJonathon R Campbell, Hamdan Al-Jahdali, Boubacar Bah, et al.
BMC Infectious Diseases|April 17, 2015
Effectiveness of RHZE-FDC (fixed-dose combination) compared to RH-FDC + Z for tuberculosis treatment in Brazil: a cohort studyJosé Ueleres Braga, Anete Trajman
Plos Medicine|June 13, 2022
Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectivenessNtwali Placide Nsengiyumva, Jonathon R Campbell, Olivia Oxlade, et al.
Epidemiologia E Servicos De Saude : Revista Do Sistema Unico De Saude Do Brasil|January 29, 2025
COVID-19 mortality among international migrants in Brazil: spatio-temporal analysis, 2020-2022João Roberto Cavalcante, Anete Trajman, Eduardo Faerstein
Revista De Saude Publica|January 15, 2026
Profile of deaths and causes of mortality among international migrants in Brazil, 2011-2022João Roberto Cavalcante, Anete Trajman, Eduardo Faerstein
BMJ Open Respiratory Research|September 15, 2025
Estimated costs of tuberculosis services in Brazil, 2023Elias Jabbour, Marcia Pinto, Ricardo E Steffen, et al.
The Lancet. Infectious Diseases|December 24, 2019
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trialsJonathon R Campbell, Anete Trajman, Victoria J Cook, et al.
Pageof 18